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Abstract
Granulin (GRN) mutations have been identified as a major cause of frontotemporal lobar degeneration (FTLD) by haploinsufficiency
mechanism, although their effects on brain tissue dysfunction and damage still remain to be clarified. In this study, we investigated the
pattern of neuroimaging abnormalities in FTLD patients, carriers and noncarriers of GRN Thr272fs mutation, and in presymptomatic
carriers. We assessed regional gray matter (GM) atrophy, and resting (RS)-functional magnetic resonance imaging (fMRI). The functional
connectivity maps of the salience (SN) and the default mode (DMN) networks were considered. Frontotemporal gray matter atrophy was
found in all FTLD patients (more remarkably in those GRN Thr272fs carriers), but not in presymptomatic carriers. Functional connectivity
within the SN was reduced in all FTLD patients (again more remarkably in those mutation carriers), while it was enhanced in the DMN.
Conversely, presymptomatic carriers showed increased connectivity in the SN, with no changes in the DMN. Our findings suggest that
compensatory mechanisms of brain plasticity are present in GRN-related FTLD, but with different patterns at a preclinical and symptomatic
disease stage.
© 2012 Elsevier Inc. All rights reserved.
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Frontotemporal lobar degeneration (FTLD) is a neu-
rodegenerative disorder characterized by behavioral ab-
normalities, language impairment, and deficits of execu-
tive functions as most typical clinical features (McKhann
et al., 2001; Neary et al., 1998). FTLD has a strong
genetic background with about 50% of patients showing
a positive family history for dementia (Rademakers and
Rovelet-Lecrux, 2009). FTLD pathophysiology has long
been referred to the presence of mutations in microtu-
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Spillantini and Goedert, 1998), which were first identified
in families with FTLD-Parkinsonism and tau-positive
inclusions, as assessed by postmortem investigation. For
a decade, gene mutations for MAPT have been regarded
as the key player for monogenic FTLD, with more than
40 mutations that have been identified so far (http://
www.molgen.ua.ac.be/FTDmutations). More recently, an
exciting breakthrough in the search of novel causal FTLD
genes was provided by identification of loss-of-function
mutations for Granulin (GRN) (Baker et al., 2006; Cruts
et al., 2006). To be considered pathogenetic, these mu-
tations are expected to induce a loss of 50% functional
progranulin (PGRN), with a mechanism of haploinsuffi-
ciency (Rademakers and Rovelet-Lecrux, 2009). In less
than 4 years, more than 60 different pathogenetic muta-
tions for GRN have been reported in literature (http://
www.molgen.ua.ac.be/FTDmutations). In the presence of
GRN gene mutation, FTLD segregates in a Mendelian
fashion, which is compatible with an autosomal dominant
inheritance (Cruts and Van, 2008). The physiological
role, as well as the effect of reduction of PGRN in the
brain tissue are still largely unknown, although it has
been recently suggested that PGRN might act as a neu-
rotrophic factor (Van Damme et al., 2008). Soon after the
discovery of GRN mutations, the nuclear protein TAR
DNA-binding protein 43 (TDP-43) was identified as the
major protein that plays a pathogenetic role in all FTLD
cases associated with GRN mutations (Neumann et al.,
2006). The underlying mechanism from which PGRN
haploinsufficiency determines TDP-43 inclusions and,
subsequently, brain damage and the clinical onset of
disease is unknown. The behavioral (bvFTD) and the
progressive nonfluent aphasia (PNFA) variants of FTLD
are the most typical presentations in GRN mutation car-
riers, with a clinical onset in the 5th and 6th decades of
life (LeBer et al., 2008; Masellis et al., 2006; Mesulam et
al., 2007; Rademakers et al., 2007; Snowden et al., 2006;
Van Deerlin et al., 2007).
Against this large background of improvements in char-
acterizing FTLD genetics, the relationship between molec-
ular aspects of pathogenesis, and structural and functional
modifications of the brain tissue still remains to be clarified.
Imaging genetics is a rapidly emerging field that is opening
up a new landscape of discovery in neuroscience (Thomp-
son et al., 2010). In this context, magnetic resonance imag-
ing (MRI) has become an increasingly popular tool for
human brain investigation in vivo. MRI has the unique
ability to provide quantitative information on both brain
tissue structure and functioning. Voxel-based morphometry
(VBM) is currently regarded as a robust magnetic resonance
technique suitable for assessing structural gray matter (GM)
modifications in an unbiased fashion (Bozzali et al., 2008;
Gorno-Tempini et al., 2004). On the other hand, resting
state functional MRI (fMRI) has shown the ability to pro-vide measures of functional brain connectivity (Biswal et
al., 1995; De Luca et al., 2005; Fox and Raichle, 2007).
Functional connectivity is a concept based on the evidence
that different brain regions present with synchronous pat-
terns of activity at rest. Those regions are likely to be part
of common networks subserving complex brain functions.
In the presence of pathology, the loss of brain connectivity
may account for some cognitive disabilities, and even for
some gray matter loss secondary to neuronal disconnection
(Gili et al., 2011). From resting state fMRI data (i.e., fMRI
time series collected while subjects lie vigilant but at rest in
the scanner), several networks can be extracted at the same
time in a data-driven fashion, using independent component
analysis (Greicius et al., 2003). The default mode network
(DMN) is by far the most extensively studied network. This
is believed to be relevant for specific higher level functions,
such as the working memory, mind wandering, and goal-
directed behaviors (Fox and Raichle, 2007). The so-called
salience network (SN) is another interesting resting state
fMRI component, which is believed to be particularly in-
formative when investigating patients with FTLD (Zhou et
al., 2010). It is characterized by a more anterior anatomical
distribution, and it has been related to behavioral and emo-
tional functions. In a recent work, Zhou and coworkers
(Zhou et al., 2010) have assessed changes in both the DMN
and the SN in patients with FTLD and Alzheimer’s disease
(AD), demonstrating a reversed pattern of abnormalities in
the 2 diseases. AD, as also demonstrated by others (Gili et
al., 2011; Greicius et al., 2004), is characterized by a re-
markable disruption of the DMN. In contrast, SN has been
reported to be selectively damaged in patients with FTLD.
The hypothesis of a selective involvement of a specific
network in either form of dementia is supported by the
observation that the pattern of atrophy typically observed in
AD overlaps with the DMN in healthy subjects (Seeley et
al., 2009), while the pattern of atrophy observed in FTLD
overlaps with the SN (Zhou et al., 2010). Furthermore, an
increase of connectivity within the DMN (Zhou et al., 2010)
has been reported in FTLD, a result which could be sug-
gestive of a compensatory mechanism. However, this inter-
pretation would need to be corroborated by data obtained in
patients at early (or preclinical) stages.
Monogenic FTLD represents a unique opportunity to
investigate the pathophysiology of FTLD in its preclinical
stages, thanks to the possibility to identify carriers of patho-
genetic mutations as at-risk individuals. Our group has
previously identified a genetically coalescent cohort of fam-
ilies with GRN Thr272fs in Italian patients with FTLD
(Borroni et al., 2008a, 2008b, 2011a), and has demonstrated
that these families harbor a common ancestor dating back to
the Neolithic era (Borroni et al., 2011a).
Taking advantage from a unique large pedigree with
different generations available, principal aims of the current
study were: (1) to confirm on a larger population of subjects,
structural and functional changes that have been previously
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(2) to investigate the effect of GRN mutation on both brain
tissue structure and function, moving from the preclinical to
the manifest stage of FTLD.
2. Methods
2.1. Subjects
Sixty-one individuals, recruited from the Centre for
Ageing Brain and Neurodegenerative Disorders, at Uni-
versity of Brescia (Brescia, Italy), were enrolled for the
current study. For the aim of the work, subjects’ recruit-
ment followed the strategy summarized in Fig. 1A. From
a large pool of almost 250 patients with FTLD (all
genetically characterized for the presence/absence of
GRN and MAPT mutations), those identified as carriers of
GRN Thr272fs mutation were invited to take part in the
current study, and 7 of them accepted. Their asymptom-
atic siblings were also invited, this implying for them to
undergo MRI scanning as well as genetic assessment of
mutation for GRN Thr272fs. As previously demonstrated,
all individual carriers of GRN Thr272fs mutation (asymp-
tomatic or symptomatic) within a large geographic area
of northern Italy, had a common ancestor who is consid-
ered as belonging to the same pedigree (Borroni et al.,
2011a). Among 22 available asymptomatic siblings, 9 of
them were found to be GRN Thr272fs mutation carriers.
The remaining 13 (noncarriers of mutation) served as
control group for the asymptomatic carriers. Asymptom-
atic mutation carriers and noncarriers were part of a
genetically homogeneous population, as they all came
from the same 6 families. This latter aspect makes our
experimental design well controlled, as the presence/
absence of GRN Thr272fs mutation is the only critical
variable between the 2 groups. Twenty-one FTLD pa-
tients (taken from the same pool of 250 individuals),
noncarriers of GRN Thr272fs mutation, were also en-
rolled in the study. They had to match for age, gender,
and phenotype with the group of FTLD GRN Thr272fs
mutation carriers. Finally, 11 healthy elderly individuals,
unrelated to the patients, were also recruited and served
as controls for both FTLD patient carriers and noncarriers
of GRN Thr272fs mutation. Five subjects (all patients
with FTLD, noncarriers of GRN Thr272fs mutation) were
excluded from MRI analysis, due to the poor quality of
their imaging data (movement artifacts). The remaining
56 subjects were therefore divided in the following ex-
perimental groups (Fig. 1B): (1) FTLD patient carriers of
GRN Thr272fs mutation (n  7) (Sm); (2) FTLD
patient noncarriers of GRN Thr272fs mutation (n  16)
(Sm-); (3) asymptomatic at-risk individual carriers of
GRN Thr272fs mutation (n  9) (S-m); (4) asymptom-
atic individual nonmutation carriers (n  13) (S-m-); (5)
healthy elderly subjects (n  11). Main demographic,
genetic, and clinical characteristics of the entire popula- mtion of subjects who were considered for MRI analyses
are summarized in Table 1.
All FTLD patients met current clinical diagnostic criteria
for behavioral variant frontotemporal dementia (15 cases)
(McKhann et al., 2001; Neary et al., 1998) and PNFA (8
cases) (Gorno-Tempini et al., 2011), with a similar distri-
bution between carriers and noncarriers of GRN Thr272fs
mutation (see Table 1). To increase as much as possible the
confidence of a correct diagnosis of FTLD in patient non-
carriers of GRN Thr272fs mutation, they had to be clinically
and neuropsychologically followed-up for at least 2 years, at
the time of recruitment. In all FTLD patients and asymp-
tomatic siblings (carriers and noncarriers of PGRN Thr272fs
mutation), serum dosage of PGRN was carried out before
MRI scanning. Due to the haploinsufficiency mechanism
that has been shown to underlie GRN gene mutations, a
remarkable reduction of PGRN levels is expected by defi-
nition in mutation carriers (Sleegers et al., 2009).
Finally, all patients had an extensive neurological and
neuropsychological evaluation, a routine laboratory exami-
nation, and conventional brain MRI before entering this
study, to rule out any potential alternative diagnosis. With
respect to exclusion of signs suggestive of a concomitant
cerebrovascular disease, exclusion criteria proposed in pre-
vious studies were applied in all subjects (Serra et al., 2010).
In all recruited subjects, family history for dementia was
carefully investigated. As previously proposed by Goldman
et al. (2005), subjects were given a “Goldman score” rang-
ing from 1 to 4, where 1 identifies an autosomal dominant
family history of dementia, 2 identifies a familial aggrega-
tion of 3 or more family members with dementia, 3 identi-
fies 1 other first degree relative with dementia, and 4 iden-
tifies no or unknown family history for dementia.
Written informed consent (from the subject or from the
responsible guardian if the subject was incapable) was ob-
tained, for each procedure, before study initiation, including
blood collection from venous puncture, genetic analysis,
and MRI scanning. The work conformed to the Helsinki
Declaration and was approved by the local Ethic Commit-
tee.
2.2. Neuropsychological assessment
2.2.1. FTLD patients
A neuropsychological battery was administered to each
patient by 2 trained neuropsychologists 48 hours before the
acquisition of the MRI. It included a general cognitive evalu-
ation, using the Mini Mental State Examination (MMSE) (Fol-
tein et al., 1975), and tests specific for each cognitive domain
as reported in Table 2): Raven’s Coloured Progressive Matri-
es (Bingham et al., 1966), as a measure of reasoning; Con-
rolled Oral Word Association Test and Category Fluency test
Isaacs and Kennie, 1973), as a measures of verbal fluency;
ey’s Complex Figure Copy and Recall (Loring et al., 1990),
s a measures of visuospatial abilities and episodic long-term
emory; the Story Recall Test (Babcock and Levy, 1940), as
. Subje
2509B. Borroni et al. / Neurobiology of Aging 33 (2012) 2506–2520a measure of verbal episodic long-term memory; the Digit
Span test (Blackburn and Benton, 1957), as a measure of
short-term memory; the Trail Making Test A and B (Reitan,
1958), as measures of executive functions; and the Token Test
Fig. 1. Recruitment strategy used for the current study (A). From a pool of a
characterized for the presence of GRN and MAPT mutations), we recruite
22 asymptomatic siblings, 9 of them carriers of GRN Thr272fs mutation (m
controls for the asymptomatic mutation carriers. From the same pool of 250
mutation. Five of them were excluded from MRI analyses, due to low qual
from the general population to act as matched controls for FTLD patients(De Renzi and Vignolo, 1962), as a measure of languagecomprehension. For each administered test appropriate adjust-
ments for age and education were applied according to the
Italian normative data. Instrumental Activities of Daily Living
(IADL) (Lawton and Brody, 1969), and Basic Activities of
50 patients with frontotemporal lobar degeneration (FTLD) (all genetically
ent carriers of GRN Thr272fs mutation. From their families, we recruited
13 noncarriers (m-). These latter individuals were used as matched healthy
s, we also recruited 21 individuals with FTLD noncarrier of GRN Thr272fs
ing data (*). Finally, a group of 11 healthy elderly subjects were recruited
cts were grouped as shown in (B).lmost 2
d 7 pati
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ity imagDaily Living (BADL) (Sheikh et al., 1979) were also assessed.
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Neuropsychiatry Inventory (NPI) (Cummings et al., 1994), and
Frontal Behavioral Inventory (FBI, Part A and B) (Alberici et
al., 2007).
Table 2
Assessment of neuropsychological and behavioral profiles, and ability to
perform daily living activities in FTLD patients
Test FTLD m
(n7)
FTLD m-
(n16)
p value a
A) Neuropsychological
assessment
MMSE 16.3  12.1 23.0  6.4 0.278
Short story 3.2  3.8 7.8  4.4 0.062
Rey figure, copy 9.1  11.1 17.1  14.0 0.222
Rey figure, recall 1.9  2.9 7.5  8.0 0.106
Raven Coloured matrices 10  8.1 18.9  10.7 0.047
Digit span 3.7  2.1 4.4  1.5 0.449
Token test 17.7  13.6 25.9  9.0 0.149
Trail making test A 279.7  218.1 166.7  167.6 0.249
Trail making test B 500.0  124.0 379.3  170.1 0.197
Phonological fluency 10.0  12.1 16.3  10.2 0.175
Semantic fluency 14.0  10.0 24.1  13.3 0.076
Clock drawing 4.67  2.7 6.4  2.7 0.203
) Behavioral assessment
FBI A 16.9  8.3 7.4  5.0 0.012
FBI B 5.1  4.1 2.2  1.8 0.110
FBI AB 22.0  11.7 9.6  6.0 0.020
NPI 15.6  13.3 10.94  6.5 0.720
) Assessment of performance
in daily living activities
IADL (lost) 2.86  2.2 0.88  1.7 0.022
BADL (lost) 1.3  1.8 0.5  1.3 0.175
eported are mean  standard deviation scores obtained by patients with FTLD m
nd those with FTLD m-. Bonferroni correction is computed as follows: p  alpha/n
in the case of n  18 multiple comparisons and alpha  0.05, Bonferroni correction
would lead to p  0.003. None of the differences between the 2 subgroups (FTLD
m and FTLD m-) reached the statistical threshold (p 0.003). See text for further
details.
Key: BADL, basic activities of daily living; FBI, frontal behavior inventory; FTLD,
frontotemporal lobar degeneration; IADL, instrumental activity for daily living;
m/-, presence/absence of GRN Thr272fs mutation; MMSE, Mini-Mental State
Table 1
Main demographic, clinical characteristics, and serum PGRN dosage of s
Variable FTLD m (n  7) FTLD m- (n  16)
Age at evaluation, y 59.9 4.9 66.87.7
Gender, female % (n) 57.1 (4) 31.2 (5)
Age at onset, y 58.1  5.4 64.07.4
Phenotype 4 FV; 3 PNFA 9 FV; 7 PNFA
Disease duration, y 1.71 0.8 2.82.7
Education, y 8.0  2.3 7.12.5
FH, % (n) 71.4 (5) 0 (0)
Serum PGRN, pg/mLa 42.4  13.3 171.351.3
No significant differences were found between patients with FTLD m
(p  0.001). Gender distribution was different between elderly controls
individuals differed for gender distribution (p  0.003) and serum PGRN
2 test (statistical threshold: p  0.05). See text for further details.
Key: FH, family history as per Goldman’s score  1 (autosomal dominan
presence/absence of GRN Thr272fs mutation; PGRN, progranulin; PNFA,
a Serum PGRN levels was available in 19 FTLD (5 FTLD m and
asymptomatic m and 10 asymptomatic m-).c
Examination; NPI, Neuropsychiatric Inventory.
a Mann-Whitney test.2.2.2. Asymptomatic siblings (PGRN mutation carriers
and noncarriers)
These subjects were screened using a shorter neuropsy-
chological assessment, including the following tests:
MMSE, Controlled Oral Word Association Test and Cate-
gory Fluency, Wisconsin Card Sorting test (WCST), and
Iowa Gambling test.
2.2.3. Healthy elderly subjects
A brief formal neuropsychological assessment was used,
in each healthy elderly control, to exclude the presence of
signs suggestive for the presence of subclinical cognitive
impairment. They were all administered the MMSE (for
which they had to report a score of 28.0 or higher) and the
IADL (for which no sign of impairment was accepted).
2.3. Granulin sequencing and serum progranulin levels
Genomic DNA was extracted from peripheral blood us-
ing a standard procedure. All the 12 exons plus exon 0 of
GRN, and at least 30 base pairs (bp) of their flanking introns
were evaluated by polymerase chain reaction (PCR) and
subsequent sequencing. GRN Thr272fs (g.1977_1980 del-
ACT) was tested as previously described (Borroni et al.,
008a, 2008b).
Serum levels of PGRN were measured, in duplicate,
sing commercial enzyme-linked immunosorbent assay
ELISA) kit (Human Progranulin ELISA kit; Adipogen Inc.,
eoul, Korea). All tests for each sample were performed
ith ELISA kits of the same lot to reduce assay variability.
iological measurements were blinded to clinical diagno-
es.
.4. Statistics
SPSS package (v. 17.0, Chicago, IL, USA) was used to
un statistics for group differences in demographic and
ubjects
derly controls (n  11) Asymptomatic m
(n  9)
Asymptomatic m-
(n  13)
.0  9.9 40.111.7 40.57.8
.7 (8) 15.4 (2) 84.6 (11)
— —
— —
— —
9.55.8 11.63.4 10.73.1
0 (0) — —
A 43.87.2 164.030.1
LD m-, with the exception of FH (p  0.001) and serum PGRN levels
LD m- patients (p  0.041). Asymptomatic m and asymptomatic m-
 0.001). Group comparisons were performed by Mann-Whitney test or
se); FTLD, frontotemporal lobar degeneration; FV, frontal variant; m/-,
ssive nonfluent aphasia.
D m-) patients and 18 asymptomatic siblings of FTLD m patients (8tudied s
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assessed by Mann-Whitney test or 2 test, setting the sta-
istical threshold to p values  0.05. When testing for
ifferences in neuropsychological and behavioral character-
stics (for which multiple measures are considered), Bon-
erroni’s correction for multiple comparisons was applied.
.5. MRI acquisition
All imaging was obtained using a 1.5 T magnetic reso-
ance scanner (Siemens Symphony, Erlangen, Germany),
quipped with a circularly polarized transmit-receive coil.
n a single session, the following scans were collected from
ach studied subject:
(1) Dual-echo turbo spin echo (TSE) (repetition time
TR]  2500 ms, echo time [TE]  50 ms), to exclude
he presence of macroscopic brain abnormalities, accord-
ng to exclusion criteria; (2) 3D magnetization-prepared
apid gradient echo (MPRAGE) T1-weighted scan (TR 
010 ms, TE  3.93 ms, matrix  1  1  1, in-plane
eld of view [FOV]  250  250 mm2, slice thickness 
mm, flip angle  15°); and (3) T2*-weighted echo
lanar (EPI) sensitized to blood oxygen level dependent
BOLD) contrast (TR  2500 ms, TE  50 ms, 29 axial
lices parallel to anterior commisure–posterior commis-
re line (AC-PC) line, matrix  64  64, field of view 
24 mm, slice thickness  3.5 mm) for resting state
MRI. Blood oxygen level dependent EPI images were
ollected during rest for an 8-minute period, resulting in
total of 195 volumes. During this acquisition, subjects
ere instructed to keep their eyes closed, not to think of
nything in particular, and not to fall asleep.
.6. Image analysis
Dual echo turbo spin echo images were carefully re-
iewed to exclude the presence of signs suggestive of cere-
rovascular disease, according to the inclusion criteria
Serra et al., 2010).
T1-weighted images from all recruited subjects were
isually inspected for a qualitative assessment of macro-
copic atrophy, and to check for the quality of data before
arrying out a quantitative volumetric analysis.
.7. Voxel-based morphometry (VBM)
Magnetization-prepared rapid gradient echo data were
rocessed using the VBM protocol in Statistical Parametric
apping 8 (SPM8; Wellcome Department of Imaging Neu-
oscience; www.fil.ion.ucl.ac.uk/spm/). For each subject, an
terative combination of segmentations and normalizations
implemented within the “Segment” SPM8 module) pro-
uced a GM probability map (Ashburner and Friston, 2005)
n Montreal Neurological Institute (MNI) coordinates. To
ompensate for compression or expansion during warping
f images to match the template, GM maps were “modu-
ated” by multiplying the intensity of each voxel by the local
alue derived from the deformation field (Jacobian deter-inants) (Ashburner and Friston, 2001). All data were
hen smoothed using a 12-mm full width half maximum
FWHM) Gaussian kernel. Modulated and smoothed GM
ere analyzed in SPM8, using a full factorial design. Sub-
ects were modeled in 5 separate groups: patients with
TLD GRN Thr272fs mutation carriers (n  7); patients
ith FTLD nonmutation carriers (n  17); healthy elderly
ubjects (n  11); asymptomatic subjects nonmutation car-
iers (young healthy subjects; n  13); and asymptomatic
ubjects FTLD GRN Thr272fs mutation carriers (n  9).
Additionally, age, gender, and years of formal education
were added as covariates of no interest. The GM maps
analysis was also adjusted for the total intracranial volume
(ICV  GM volume  white matter volume  cerebrospi-
nal fluid volume). Contrasts were designed to assess (1) the
effect of symptoms and mutation in regional GM volumes
by comparing FTLD patients with healthy elderly subjects,
(2) the effect of mutation in preclinical stages by comparing
asymptomatic subjects GRN Thr272fs mutation carriers
against those nonmutation carriers (young healthy subjects);
and (3) the interaction between the presence of symptoms and
the presence of GRN Thr272fs mutation.
For every T-contrast, we applied family-wise error
(FWE) correction for multiple comparisons, and we ac-
cepted as significant p values of less than 0.005 at cluster
level.
2.8. fMRI data analysis
Resting state fMRI data were preprocessed using SPM8
for image preprocessing and statistical comparison, and the
Group independent component analysis (ICA) for fMRI
toolbox (GIFT, icatb.sourceforge.net/) for ICA.
For each subject the first 4 volumes of the fMRI series
were discarded to allow for T1 equilibration effects. The
preprocessing steps included correction for head motion,
compensation for slice-dependent time shifts, normalization
to the EPI template in Montreal Neurological Institute co-
ordinates provided with SPM8, and smoothing with a 3D
Gaussian Kernel with 8 mm3 FWHM. Then, all images
were filtered by a phase-insensitive bandpass filter (pass
band 0.01–0.08 Hz) to reduce the effect of low frequency
drift and high frequency physiological noise. ICA analysis
was employed to identify 20 independent components.
Briefly, group ICA for fMRI toolbox first concatenates the
individual data across time, and then produces a computa-
tion of subject specific components and time courses. For all
subjects grouped together, the toolbox performed the anal-
ysis in 3 steps: (1) data reduction, (2) application of the
FastICA algorithm, and (3) back-reconstruction for each
individual subject (De Luca et al., 2006). Results were
converted to Z-scores. The 20 components were reviewed,
and compared, by computing the spatial correlation coeffi-
cient, to customized templates of the SN and of the DMN.
These templates were obtained from an independent sample
of 28 healthy subjects (13 females, mean age 38.6 years, SD
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spatial sorting of the components available with GIFT.
Every subject’s Z-score maps corresponding to these 2 rest-
ing state networks were used for cross-subject analyses. A
random-effect analysis was carried out using a full factorial
design in SPM8. As for the VBM analysis, a full factorial
design was used for both SN and DMN. Subjects were
divided into 5 separate groups: patients with FTLD GRN
Thr272fs mutation carriers (n  7); patients with FTLD
nonmutation carriers (n 16); healthy elderly subjects (n
11); asymptomatic subjects nonmutation carriers (young
healthy subjects; n 13); and asymptomatic subjects FTLD
GRN Thr272fs mutation carriers (n 9). Age, gender, years
of education, and total GM volumes (as derived by VBM
analysis) were entered as covariates of no interest.
For each considered network (SN and DMN), contrasts
were designed to assess (1) the effect of symptoms and
mutation in functional connectivity by comparing FTLD
patients with healthy elderly subjects, (2) the effect of mu-
tation in preclinical stages of disease by comparing asymp-
tomatic subjects GRN Thr272fs mutation carriers with those
nonmutation carriers (young healthy controls); and (3) the
interaction between the presence of symptoms and the pres-
ence of GRN Thr272fs mutation on the functional brain
connectivity.
In patients only, we performed a multiple regression
analysis to assess the presence of correlations between the
MMSE (a measure of global cognition) and functional con-
nectivity within the SN and the DMN. The analysis was
adjusted for age, gender, years of education, and total GM
volume. p values were considered significant if less than
0.05, after FWE correction at cluster level.
3. Results
3.1. Demographic, clinical, and laboratory
characteristics of studied subjects
There was no significant difference in age (p  0.08),
gender (2  1.05; df  1; p  0.31), age of clinical onset
p  0.10), disease duration (p  0.54), and clinical phe-
notypes distribution (2  0.0016, df  1; p  0.97)
etween FTLD patients carriers and noncarriers of GRN
hr272fs mutation (see Table 1). As expected, FTLD car-
iers of GRN Thr272fs mutation had a higher rate of positive
amily history for dementia (Goldman’s score  1; 66.4%)
han FTLD noncarriers (0%; p  0.001) (see Table 1).
onsistent with genetic assessments, the former group had
ignificantly lower serum levels of PGRN than the latter
roup (p  0.001) (see Table 1).
There was no significant age difference between asymp-
omatic subjects with and without GRN Thr272fs mutation.
onversely, gender distributions were different between the
groups. As expected, asymptomatic GRN Thr272fs muta-
ion carriers had lower serum levels of PGRN than asymp-
omatic noncarriers (p  0.001) (see Table 1). t.2. Neuropsychological and behavioral measures, and
ssessment of performances in daily living activities
As reported in Table 2, the level of global cognitive
mpairment as well as that of functional impairment were
omparable between the 2 groups of patients with FTLD.
pecific neuropsychological tests and behavioral measures
id not reveal any significant difference between the 2
roups.
According to inclusion criteria, all elderly healthy con-
rols had to report MMSE scores higher than 28.0, and
ormal performance at IADL.
All asymptomatic subject carriers of GRN Thr272fs mu-
ation reported the maximum score at the MMSE, and per-
ormed within the normal range at any other administered
est. The between group comparison did not reveal any
ifference at any test.
.3. MRI data
.3.1. Visual inspection of T1-weighted images
T1-weighted images from the FTLD patient carriers of
RN Thr272fs mutation are shown in Fig. 2. Visual inspec-
ion revealed an asymmetric distribution of atrophy (more
emarkable on the left hemisphere) in 4 out of 7 patients
subjects 1, 2, 5, and 7). Five out of 7 patients showed a
ore severe atrophy in the frontal lobes (subjects 1, 2, 4, 5,
nd 7), while the other 2 had a more posterior distribution of
trophy (subjects 3 and 6). Patients with sporadic FTLD
evealed patterns of frontotemporal atrophy consistent with
he diagnosis. T1-weighted images from asymptomatic
RN Thr272fs mutation carriers did not reveal any macro-
copic abnormality, and, according to experienced radiolo-
ists were nondistinguishable from those of healthy subjects
f comparable age. Consistent with aging related processes,
lderly healthy subjects had (on average) larger ventricles
han younger controls, in the absence of pathological
hanges.
As mentioned above, scans from 5 patients with sporadic
TLD revealed the presence of movement artifacts, and
ere excluded from VBM analysis.
.3.2.VBM
Patients with FTLD (Sm and Sm-) compared alto-
ether with healthy age matched elderly controls (ES-m-)
ad reduced GM volume in the left frontotemporal cortex
Fig. 3A). An additional reduction of GM volume was
ound in the left frontal cortex of FTLD patients GRN
utation carriers when compared with those without GRN
athogenetic mutations (Sm  Sm-) (see Fig. 3A).
Asymptomatic carriers of GRN Thr272fs mutation (S-m)
ompared with asymptomatic noncarriers (S-m-) did not reveal
ny significant difference in regional GM volumes. The symp-
om by GRN Thr272fs mutation interaction revealed a neg-
tive effect of mutation on the GM volumes in the left
nsular cortex that, however, did not survive FWE correc-
ion (p uncorrected  0.001).
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Among the 20 components modeled in the ICA analysis,
several well-known resting state networks were identified,
including the SN, the DMN, the sensory-motor network,
and the visual network.
The main effect of group (including all studied subjects)
for the salience and the default mode network are shown in
Fig. 4.
The analysis of the SN revealed 4 clusters of reduced
functional connectivity in patients with FTLD compared
altogether (Sm and Sm-) against elderly healthy con-
rols. These clusters of reduced functional connectivity were
ocalized in the frontal lobe of FTLD patients bilaterally
Fig. 5A). In contrast, the asymptomatic mutation carriers
S-m) compared with age-matched young healthy controls
Y S-m-) showed a medial frontal area of increased con-
ectivity (Fig. 5B).
The direct comparison between FTLD patients GRN
Thr272fs mutation carriers and those nonmutation carriers
revealed a reduction of connectivity in the left prefrontal
cortex of the former group (i.e., Sm  Sm-; p uncor-
rected  0.001) that, however, does not survive FWE cor-
Fig. 2. Axial T1-weighted images from the frontotemporal lobar degener
images reveals an asymmetric distribution of atrophy (left more than righ
is prominent in subjects 1, 2, 4, 5, and 7. Conversely, subjects 3 and 6 sh
L, left; R, right.rection. dThe symptom by GRN Thr272fs mutation interaction
revealed a negative effect of mutation on the functional
connectivity in the left prefrontal cortex that, again, did not
survive FWE correction (p uncorrected  0.001).
The analysis of the DMN revealed a significant increase
of functional connectivity in the left angular gyrus of FTLD
patients compared altogether (Sm and Sm-) with el-
derly healthy controls (Fig. 6A). A significant symptom by
GRN Thr272fs mutation interaction (p-FWE cluster level
corrected  0.05) was observed in the posterior cingulate
ortex and in the left temporal lobe (Fig. 6B).
No significant correlation was found between functional
onnectivity within the SN and the DMN and patients’
MSE score.
. Discussion
In this MRI study, we recruited a large population of
atients, part of them suffering from the sporadic form of
TLD, some of them carriers of GRN Thr272fs mutation.
urther, for the first time, we investigated a group of GRN
hr272fs mutation carriers in a presymptomatic stage of
TLD) patients carriers of GRN Thr272fs mutation. Visual inspection of
phere) in 4 out of 7 patients (subject 1, 2, 5, and 7). Frontal involvement
attern of brain atrophy with a more posterior distribution. Abbreviations:ation (F
t hemis
ow a pisease. This latter aspect is the main strength of the current
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nuclear kindreds, a relatively large group of family mem-
bers bearing the same pathogenic GRN Thr272fs mutation,
ll descending from a common ancestor. This represents an
xtraordinary naturalistic experimental model to recon-
truct, by advanced MRI techniques, the impact of GRN
hr272fs mutation on the brain tissue structural and func-
ional characteristics.
When investigating the main effect of symptoms (re-
ardless of presence/absence of GRN Thr272fs mutation),
BM analysis revealed a well defined pattern of regional
M atrophy, which mainly involved the left frontotem-
oral areas (see Fig. 3A). This anatomical distribution of
tructural brain damage is consistent with that reported
y others (Beck et al., 2008; Rohrer et al., 2010), and fits
ell with the cognitive and behavioral aspects typically
bserved in FTLD. Moreover, as shown here for the first
ime, this damage is remarkably prominent in the pres-
nce of GRN Thr272fs mutation. Although, due to our
election criteria, cognitive and behavioral disabilities
ere not significantly different between FTLD groups
Fig. 3. VBM analysis. (A) Main effect of frontotemporal lobar degenera
predominantly involves the left prefrontal cortex; (B) additional GM loss i
mutation carriers. Statistical threshold: p values FWE cluster level correc
ubjects; FWE, family-wise error; S-m, asymptomatic carriers of GRN Th
Sm-, FTLD patients nonmutation carriers; Y S-m-, young healthy subjewith and without GRN Thr272fs mutation), our findings suggest that the presence of GRN Thr272fs mutation may
ct as an independent contributor in determining brain
issue damage. This is in line with recent evidence of a
orse prognosis in GRN mutation carriers as compared
ith sporadic FTLD (Borroni et al., 2011b).
Consistent with the findings recently reported by Zhou
t al. (2010), our resting state fMRI analysis revealed a
elective disruption of the SN in the presence of FTLD
athology (Fig. 5A). This network is believed to be
mplicated in behavioral functioning and emotion pro-
essing, thus accounting for some critical features of
TLD. Similarly to the distribution of GM atrophy, the
nvolvement of the SN was also more marked in FTLD
utation carriers than in mutation noncarriers (Fig. 5A).
symptomatic GRN mutation carriers showed an in-
rease in functional connectivity within the SN (Fig. 5B).
espite the absence of direct associations between this
hange in functional connectivity and cognitive data, we
an speculate that this enhancement may compensate for
he effects of reduced PGRN at early stages, thus ac-
ounting for the absence of symptoms at preclinical
TLD) showing an extensive pattern of gray matter (GM) atrophy which
ft prefrontal cortex of FTLD patients as an effect of being GRN Thr272fs
0.005. See text for further details. Abbreviations: ES-m-, elderly healthy
mutation; Sm, patients with FTLD carriers of GRN Thr272fs mutation;tion (F
n the le
ted 
r272fstages.
2515B. Borroni et al. / Neurobiology of Aging 33 (2012) 2506–2520The DMN, consistent with previous findings (Zhou et al.,
2010), was found to be enhanced in the presence of FTLD
(Fig. 6A). Again, we were unable to demonstrate any direct
association between patients’ cognitive data and changes in
functional connectivity within the DMN. Nevertheless, this
enhanced connectivity within the DMN of FTLD patients
might represent a compensation mechanism of brain plas-
ticity in the presence of a disease that selectively targets
neurons in the frontotemporal areas. Further, the enhance-
ment of the DMN (in contrast with the disruption typically
observed in patients with AD) is in line with the typical
cognitive profile observed in FTLD patients, which is
characterized by a relative preservation of memory func-
tions. As observed in the VBM analysis, the presence of
GRN Thr272fs mutation seems to make the pattern of
functional brain abnormalities worse. Indeed, an area
of negative group  mutation interaction was observed
within the DMN (Fig. 6B). This suggests an early en-
hancement of connectivity at preclinical stages (GRN
Thr272fs mutation carriers), but a reduction in FTLD
patients GRN Thr272fs mutation carriers as compared
with mutation noncarriers. This finding, taken together
with the evidence of increase connectivity in the SN of
asymptomatic carriers, allows us to speculate that 2 dif-
Fig. 4. Main effect of group (including all studied subjects) for the salien
family-wise error corrected  0.005.ferent compensatory mechanisms may coexist in FTLDbrains. As reported in Fig. 7, in a preclinical stage, we
observe an enhancement in the SN, which is the main
target of pathology. This mechanism is likely to be tem-
porary, and, when it fails, the symptoms become evident.
At this stage, a second mechanism of compensation may
be observed within the DMN.
The relationship between our current neuroimaging find-
ings and the molecular mechanisms underlying neuronal
firing patterns closer to PGRN action, are complex and still
not elucidated. The GRN gene encodes a secreted multi-
functional growth factor involved in tissue remodeling,
wound repair, and inflammation (Baker et al., 2006; Cruts et
al., 2006). In the brain tissue, where PGRN is expressed in
both neurons and microglia, its functions have not yet been
studied extensively. However, it has been recently sug-
gested that PGRN may play a role in neuronal development
and in neuronal survival (Baker et al., 2006; Cruts et al.,
2006; Kleinberger et al., 2010).
As already mentioned above, more than 60 pathogenetic
GRN mutations have been described so far, and they are all
expected to cause PGRN haploinsufficiency (Alzheimer
Disease and Frontotemporal Dementia Database; http://
www.molgen.ua.ac.be/FTDmutations/). The mechanisms
by which PGRN loss-of function leads to the neuropatho-
t side) and the default mode network (right side). Statistical threshold: pce (leflogical hallmark of GRN-related FTLD, namely TDP-43
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sions (Neumann et al., 2006), is still largely unknown.
The present study, for the first time, provides a model to
characterize in vivo the brain changes occurring in cases of
PGRN inherited disorder, from the preclinical to the symp-
tomatic stages.
The presymptomatic subjects, carriers of GRN Thr272fs
utation, showed normal performances at an extensive cog-
itive and behavioral assessment, as further supported by
he follow-up evaluation of the original group sample (Bor-
oni et al., 2008a). Conversely, in preclinical carriers of
APT mutation, deficits in language and executive function
ere detectable even 20 years before clinical onset (Ge-
chwind et al., 2001). A possible explanation for these
bservations is that, in PGRN presymptomatic subjects,
ormal cognition is maintained by the compensatory mech-
nism of increased connectivity within the SN. At present,
e are unable to hypothesize which possible patterns of
unctional connectivity might be present in the brain of
symptomatic MAPT mutation carriers. Future studies, in-
Fig. 5. Salience network functional connectivity. (A) Pattern of reduced
compared with age- and gender-matched healthy controls (main effect of
(B) A region of the salience network where asymptomatic carriers showed
the green circle highlights the cluster to which the plot refers. Statistical t
further details. Abbreviations: ES-m-, elderly healthy subjects; S-m, asym
of GRN Thr272fs mutation; Sm-, FTLD patients nonmutation carriers; Yluding subjects with different kinds of mutation, are needed To clarify whether similar or distinct network rearrangements
re modulated by different genetic defects. For example, it
emains to be clarified whether the mechanisms of brain plas-
icity that we observed in the current study, occur exclusively
n cases of “loss of function,” such as in PGRN haploinsuffi-
iency, or also in others. Another point that needs addressing,
s how the human brain may cope with different molecular
echanisms, such as the abnormal tau deposition and protein
ain of function observed in MAPT disease.
As already stated, this is the first study that used resting
tate fMRI to investigate asymptomatic carriers of GRN mu-
ations. There is only a previous report that used VBM and
iffusion tensor MRI to respectively assess changes in GM and
hite matter of a small group of asymptomatic carriers. Con-
istent with our current findings, no changes were found in
egional GM volumetrics. Conversely, microscopic abnormal-
ties were detectable in the left uncinate fasciculus and in the
nferior fronto-occipital fasciculus (Borroni et al., 2008a).
This study entails some limitations. First, it was only
ocused on a homogeneous kindred, carrying the GRN
tivity in all patients with frontotemporal lobar degeneration (FTLD) as
ms), together with a plot of contrast estimates at the maximum T values.
ed connectivity compared with matched healthy controls. For each panel,
d: p values cluster level family-wise error corrected  0.05. See text for
ic carriers of GRN Thr272fs mutation; Sm, patients with FTLD carriers
young healthy subjects.connec
sympto
increas
hreshol
ptomathr272fs mutation. This means that our results cannot be
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iterature. Nevertheless, as GRN mutations all share a com-
on loss-of-function effect, it is likely that similar MRI
hanges might be found also in other pathogenetic varia-
ions. Second, in asymptomatic carriers a more detailed
ognitive assessment would be needed, in order to eval-
ate in-depth subtle cognitive deficits, such as executive
ysfunctions. Third, if the diagnostic process was rela-
ively easy in FTLD patients bearing GRN mutation,
utopsy confirmation in cases suffering from a nonmono-
enic disease would be warranted. Nevertheless, this
atter group did not represent the main focus of the
urrent work. Moreover, the pattern of MRI changes we
bserved in our group of patients without GRN-mutation
s comparable with that reported in previous studies
Beck et al., 2008; Rohrer et al., 2010), thus suggesting
he accuracy of the diagnostic process. Fourth, we were
nable to detect associations between measures of global
ognition and the strength of connectivity in the SN and
n the DMN of FTLD patients. This lack of correlation
Fig. 6. Default mode network (DMN) functional connectivity. (A) Pattern
(FTLD) as compared with age- and gender-matched healthy controls (mai
T values. (B) Areas of the DMN, in which FTLD patients GRN Thr272f
educed connectivity, and relative plot of contrast estimates in the 5 group
tatistical threshold: p values cluster level family-wise error corrected 
Sm, patients with FTLD carriers of GRN Thr272fs mutation; Sm-, FT
mutation. YS-m-, young healthy subjects.ight be due to the small sample size, and needs to beurther investigated in future studies on larger popula-
ions. Finally, a comprehensive work evaluating both
hite matter abnormalities and functional connectivity
hanges would be desirable.
In conclusion, this study has tried to unravel the pattern
f neuroimaging abnormalities in FTLD patients, carriers,
nd noncarriers of GRN Thr272fs mutation, and in presymp-
omatic carriers. Understanding the GRN-associated pre-
linical changes and how the molecular process influences
unctional brain connectivity, is a crucial step to identify a
otential target for any evidenced-based treatment for at-
isk individuals, and to monitor the effects of intervention.
o meet this goal, it is mandatory to establish whether GRN
utations lead to brain plasticity compensatory mechanisms
nd how these abnormalities converge into neurodegenera-
ion in later life.
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